Tirzepatide

Eli Lilly’s retatrutide, a triple hormone receptor agonist, has demonstrated an average weight loss of 28.3% over 80 weeks on the highest dose in Phase 3 trials. While this is more than the average weight loss of other GLP-1 drugs, the medicine comes with increased severity of side effects. Common side effects include nausea and…

The New York Times published a profile of the company Medvi earlier this month, celebrating it as an example of what AI could help a single person do: build a telehealth company its founder projects will be worth $1.8 billion this year despite a closing loophole for telehealth companies selling compounded versions of popular metabolic…

In 2024, OpenAI CEO Sam Altman predicted that a single entrepreneur using AI would generate a business worth more than one billion dollars. The L.A. entrepreneur Matthew Gallagher apparently is boasting that his telehealth startup MEDVi is among the first companies to make good on that prediction. On LinkedIn, he has called the firm, which…

The Pharma 50 has a new company sitting at the top: Eli Lilly, which last year was in the ninth slot. The next question is how long it can stay there, because pharma sector leadership is, historically, something of a revolving door. Right now, Lilly’s lead is razor thin. Just $170 million separated Eli Lilly’s…

Novo Nordisk’s triple agonist UBT251 delivered a mean weight loss of 19.7% after 24 weeks in a Phase 2 trial in China, the company announced on Tuesday. UBT251 is a triple agonist of the receptors for GLP-1, GIP and glucagon (triple G) and is being jointly developed with United Biotechnology.  The trial was conducted by…

Novo Nordisk’s latest weight loss treatment, CagriSema, did not meet the primary endpoint of showing non-inferiority compared to tirzepatide, the company announced on Monday. CagriSema, a combination of cagrilintide and semaglutide, achieved 23% weight loss after 84 weeks of treatment, compared to 25.5% with tirzepatide. The treatment was safe and well tolerated, with mostly mild…

Treating obesity may directly improve psoriatic arthritis outcomes, according to Phase 3b data released Wednesday by Eli Lilly. In the TOGETHER-PsA trial, patients receiving both Zepbound (tirzepatide) and Taltz (ixekizumab) showed a 64% relative improvement in arthritis disease activity compared to those on Taltz alone. The findings suggest obesity treatment directly improves psoriatic arthritis disease…

Quarter 3 results Eli Lilly reported a 54% increase in revenue in the third quarter, rising to $17.60 billion in 2025 from $11.439 billion in 2024, which the company largely credited to sales of Mounjaro and Zepbound, the company’s GLP-1 agonist weight-loss treatments.  Mounjaro revenue saw a 109% increase in revenue from the third quarter…

Eli Lilly is on track to overtake pharma rivals and claim the industry’s top spot by late 2026, completing one of the most dramatic repositionings in Big Pharma’s recent history. Aggressive and base scenarios place Lilly’s rise to the number one slot in 2026, while a conservative prediction forecasts that the firm will do so…

It took just one off-hand comment during a White House event about fertility treatments for President Trump to temporarily wipe tens of billions from the market cap of the world’s leading obesity drugmakers. Trump’s vow Thursday to bring Ozempic down to $150 per month, calling it “the fat-loss drug,” sent Novo Nordisk shares down 6.3%…

A new case series published in JAMA Ophthalmology has spotlighted rare but potentially serious vision issues in patients taking semaglutide or tirzepatide, two popular glucagon-like peptide-1 (GLP-1) receptor agonists commonly used to treat diabetes and aid weight loss. In the investigation, nine individuals reported sudden vision changes while on semaglutide or tirzepatide; seven of these…

Eli Lilly’s hit drug tirzepatide has demonstrated a 94% reduction in the risk of developing type 2 diabetes among overweight and obese prediabetic adults, according to new findings from a 176-week Phase 3 trial. The SURMOUNT-1 study, the longest completed trial of tirzepatide to date, also showed sustained weight loss through the treatment period, with…

Ozempic is still the GLP-1 king, but Lilly is rapidly gaining market share, with its Q2 2024 sales reaching $3.01 billion compared to Novo Nordisk’s $5.38 billion. In terms of Q2 quarterly sales, Lilly’s chronic weight management therapy Zepbound in particular is growing quickly with 140% growth between Q1 and Q2. Mounjaro, which, like Zepbound…

Heart disease remains the number one killer globally, but the megablockbuster tirzepatide is proving it can do more than just help people lose weight – it’s now showing promise in fighting heart failure, too. In topline results from the phase 3 SUMMIT study, Lilly’s dual GIP/GLP-1 receptor agonist tirzepatide cut the risk of heart failure…

Today, Lilly announced promising data for the SURMOUNT-OSA phase 3 clinical trials testing tirzepatide in adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity. The company shared the data at the American Diabetes Association’s (ADA) 84th Scientific Sessions while publishing them in The New England Journal of Medicine (NEJM). The SURMOUNT-OSA phase 3 trial consists…

Eli Lilly is experiencing meteoric growth in 2024, driven by surging demand for its metabolic therapies. In the first quarter, Lilly’s revenue jumped 26% year-over-year to $8.77 billion, propelled by strong sales of diabetes drug Mounjaro and weight loss treatment Zepbound Lilly also significantly raised its full-year 2024 outlook. The company now expects revenue in…

The latest crop of glucagon-like peptide-1 (GLP-1) agonists, such as semaglutide and tirzepatide (technically, a dual GIP/GLP-1 receptor agonist), have upended the way we treat metabolic disorders, including obesity. These drugs mimic gut hormones, improving blood sugar control and often leading to significant weight loss. But as Kyasha Sri Ranjan, Ph.D., engagement manager at Lifescience…

This morning, Eli Lilly reported positive phase 2 results for its dual GLP-1 and GIP receptor agonist tirzepatide in patients with nonalcoholic steatohepatitis (NASH). In the SYNERGY-NASH trial, the therapy achieved NASH resolution without worsening fibrosis in 61.3% of patients. That is considerably higher than data for semaglutide. Picturing tirzepatide’s NASH resolution in a phase…

Lilly’s hot weight loss drug Zepbound (tirzepatide) may be one of the most effective drug therapies for weight loss. In an open-label 36-week study, participants lost an average of 20.9% of their body weight in 36 weeks. With an average weight of 107.3 kg (236.5 lbs), that equates to about 22.4 kg (49.4 lbs) on average.…

A new real-world study (pre-print) is the first to directly compare weight loss outcomes between the popular diabetes medications Lilly’s Mounjaro (tirzepatide) and Novo Nordisk’s Ozempic (semaglutide). The results show Mounjaro users are significantly more likely to achieve meaningful weight loss. Analyzing data from more than 40,000 patients from a large U.S. health database, the…

Lilly’s tirzepatide notched an FDA approval for chronic weight management, potentially clearly the way for billions in additional sales. Analysts have projected that the drug could fetch $26 billion in annual sales by 2030, with roughly two-thirds of that sum related to obesity​ treatment​. Bank of America analyst Geoff Meacham is even more optimistic, predicting…

In the phase 3 SURMOUNT-3 trial, tirzepatide recipients saw some of the most impressive weight loss results among trials of GLP-1 drugs, including most notably semaglutide. In the study, participants’ total mean weight loss was 26.6% over 84 weeks following a 12-week intensive lifestyle intervention and subsequent tirzepatide treatment. In all, participants who received tirzepatide…

Eli Lilly‘s (NYSE:LLY) tirzepatide achieved up to 15.7% weight loss in the SURMOUNT-2 study, sparking a potential tirzepatide versus semaglutide competition in the obesity and type 2 diabetes treatment markets. The phase 3 study enrolled 938 participants with diverse backgrounds. Tirzepatide promises to be a megablockbuster with a number of analysts pegging peak annual sales…

FDA has approved Mounjaro (tirzepatide), the first glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) for treating adults with type 2 diabetes. Developed by Eli Lilly and Co., tirzepatide could quickly become a mega-blockbuster. Annual sales of the drug could approach $14 billion by 2030, according to Mizuho Securities. To win approval, Lilly provided data…

Eli Lilly and Co. (NYSE: LLY) has announced that tirzepatide enabled trial participants to lose up to 22.5% of their body weight in the SURMOUNT-1 study. Study volunteers receiving tirzepatide lost up to 52 lb. (24 kg) in the 72-week Phase 3 trial. A total of 55% of those receiving a 10 mg dose lost…